AstraRazeneca plans to spend $ 50 billion in the United States to expand production and research in the United States, Monday, the latest great investment reacted to President Donald Trump’s tariff policy.
Investment will finance a new drug production facility in Virginia and expand production of Maryland, Massachusetts, California, Indiana, Research and Development (R & D) and mobile therapy.
In addition, Anglo-Sweden Drammaker will improve the US clinical test supply network and support the ongoing investment support in novel medicine.
Astrazeneca, expansion, until 2030, reaching $ 80 billion until 2030, the United States said
The United States in 2024 was 40% of more than 40% of the annual income of Astrazeneca, and the company’s market – the world’s largest, 635 billion dollars – Trump’s return.
The movement to install US traces is the latest by a druggist as Trump, threatened to apply import tariffs in industry and try to increase local production. The sector has historically been tried from trade disputes.
Instead of importing the import of Pharma companies in the country, Pharma called on Pharma to get more part of the drugs sold in the United States. He also pushes the prices in the United States to pay for other countries.
CEO Pascal Soriot has announced the plans in Washington, and “equate” and “equalize” and “equalize” and other countries “equate” and other countries. “The United States cannot build or take the price of R & D for the whole world,” he said.
The US Trading Secretary Howard Lutnick department is leading a probe to the imports of pharmaceutical import that can lead to new tariffs.
“For decades, Americans have relied on the external supply of key pharmaceutical products. President Trump and new tariff policies of our nation are aimed at completing this structural weakness,” said Lutnick Astrazeneca.
Although the Trump threatened the tariffs in the sector, the month would be given a year to “get together to 18 months before 18 months before 18 months.
The company said that although the time and place of the announcement is due to the environment of US policy, some expenditures are in the place of infrastructure for future drugs.
Collateral in November 2024, the company announced $ 3.5 billion in investment, but also $ 3.5 billion.
Niece
In exchange for $ 50 billion, Switzerland was declared by Roche and matches the new spending plans presented by Johnson & Johnson, Novartis and Sanofi.
Virginia State Governor Glenn Youngkin, who also presented an announcement, was a vocal trump ally defending the management tariff policy.
The new Virginia Institute – the company’s largest production investment – Astrazeneca will produce active ingredients for Oral GLP-1 candidate and oral PCKK9 inhibitor for Oral GLP-1 candidate and cholesterol management.
The company said that the investment can create tens of thousands of new jobs, but he refused to give their properties. About 18,000 people have been working in the United States and have about 90,000 global workers.
In January, in the northern Britain’s vaccine producer, 450 million pounds ($ 607.1 million) are planned to be determined in the government’s support.
At the beginning of this month, the company’s most valuable company of the company’s most valuable company, the Times said to be worth 159 billion pounds, the most valuable company in the United States.
($ 1 = 0.7415 pound)
-Amed Aboulenein and Maggie Fick, Reuters